Sep 19, 2021

Mawazo Writing Africa

Writing about the main

COVAX flays ‘unacceptable’ vaccine disparity between rich, poor nations

A joint statement by COVAX yesterday highlighted the alarming inequality in access to COVID-19 vaccines between rich and poor countries.

COVAX (COVID-19 Vaccines Global Access) is a global initiative with the goal of equitable access to vaccines. It is jointly convened by Gavi, the Vaccine Alliance (formerly Global Alliance for Vaccines and Immunization or GAVI), the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO).

“The global picture of the Access to COVID-19 vaccines is unacceptable. Only 20% of people in low and lower middle income countries have received a first dose of the vaccine compared to 80% in high and upper middle income countries, ”COVAX said in the statement on the supply forecast for 2021 and early 2022. < / p>

The discrepancy persists despite the fact that “COVAX has already made significant strides: more than $ 10 billion has been raised; legally binding commitments for up to 4.5 billion doses of vaccine; 240 million doses delivered to 139 countries in just six months. ”

According to the forecast, COVAX expects access to 1.425 billion vaccine doses in 2021, in the most likely scenario and with no urgent action from manufacturers and high-coverage countries to Prioritize COVAX. Of those doses, approximately 1.2 billion will be available to lower-income economies participating in the COVAX Advance Market Commitment (AMC).

This is enough to supply 20 percent of the population, or 40 percent of the population protect all adults in all 92 AMC economies with the exception of India. Over 200 million cans will be given out to self-funding participants. The key COVAX milestone of 2 billion doses released for dispensing is now expected to be reached in the first quarter of 2022.

THIS came as a new report from the Global Fund yesterday showed that the COVID-19 pandemic had had devastating effects on the fight against human immunodeficiency virus (HIV), tuberculosis (TB) and malaria in 2020.

It emerged that while some progress had been made, the main programmatic results declined for the first time in the History of the Fund.

Global Fund Executive Director Peter Sands said, “To mark our 20th anniversary, we had hoped to focus this year’s earnings report on the extraordinary stories of courage and resilience that have enables the advances we have made over the past two decades against HIV, TB and malaria. But the numbers for 2020 force a different focus. They confirm what we feared when COVID-19 strikes. “